Empresas Andrómaco Overview

Empresas Andrómaco Andr Andrómaco maco Overview
March 22nd March 22 , 2010 nd , 2010
1

Corporate Profile
� Empresas Andrómaco is one of the leading pharmaceutical companies along the Pacific Coast of Latin
America, with strong manufacturing, marketing and distribution networks for medicines, nutritional
products and medical supplies.
� The Company positions itself as a Pharmaceutical Marketing Company, specialized in Prescription and
specialized healthcare products, for private an public markets, recognized by the quality and efficiency
of commercial management.
� The Company has a strong capacity to create high demand in private and institutional markets, based
on experience, quality, and extensive outreach to medical professionals.
� Sales force of over 600 professionals
� The Company provides effective and efficient marketing channels including promotion throughout the
health care industry, among consumers, through trade organizations and existing sales and distribution
networks.
� Empresas Andrómaco is the best strategic partner for international companies interested in developing
their pharmaceutical business in Latin America.
2

History
1927 � Laboratorios Andrómaco was founded in Spain
1942 � Andrómaco launches operations in Chile
1979 � Andrómaco separates from Spanish parent company and merges with Chilean laboratories
1993 � First branch ABL Pharma Bolivia is opened
2002 � Andrómaco achieves GMP certification from the Public Health Institute (ISP) of Chile
2002 � New strategic approach EMPRESAS ANDROMACO
2004 � Andrómaco initiates share offering on Chilean stock market
2004 � The Ferrer‐Andromaco joint‐venture is inaugurated
2005 � Empresas Andrómaco buys Laboratorio Silesia
2005 � Andrómaco laboratories receives its second GMP certification from the ISP of Chile
2005 � Empresas Andrómaco achieves CENABAST certification
2006 � Andrómaco Laboratories receives INVIMA certification for all production lines
2006 � Andrómaco is ranked as number two laboratory in Chile in units
2007 � ABL Pharma Dominican Republic begins operations
2007 � Andrómaco buys IPROFASA in Guatemala
2007 � MasterCare is founded
2008 � 80% of Diagnotec is acquired
2008 � Andrómaco opens the first Biofarmaceutical Center to be approved in Chile
2009 � Number 1 supplier public sector
3

Property Structure
� Open joint‐stock company marketed in the
Commerce Stock Exchange of Santiago.
� Risk classification
� Feller Rate: first Class, Level 3
� Fitch Chile: first Class, Level 3
Sahrehoders Shares %
INVERSIONES NM LIMITADA 196,189,121 35.0%
MONEDA SA AFI PARA PIONERO FONDO DE INVERSION 80,679,000 14.4%
FONDO DE INVERSION LARRAIN VIAL BEAGLE 37,301,079 6.7%
CELFIN SMALL CAP CHILE FONDO DE INVERSIO 33,588,822 6.0%
MONEDA SA AFI PARA COLONO FONDO DE INVERSION 33,357,000 6.0%
COMPASS EMERGENTE FONDO DE INVERSION 28,655,760 5.1%
CELFIN CAPITAL S A C DE B 25,293,664 4.5%
CHILE FONDO DE INVERSION SMALL CAP 19,960,453 3.6%
INVERSIONES MARDOS SA 15,000,000 2.7%
SIGLO XXI FONDO DE INVERSION 9,542,950 1.7%
MONEDA SA AFI PARA MONEDA CHILE FUND LTD 8,928,000 1.6%
LARRAIN VIAL S A CORREDORA DE BOLSA 7,204,024 1.3%
Sub Total 495,699,873 88.43%
Other 64,840,673 11.57%
Total 560,540,546 100.00%
Corporate Ownership
US$/share
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
sep‐04
NM Private
Investor
35%
Other Share‐
holders
24%
ene‐05
0.2
may‐05
0.2
sep‐05
ene‐06
0.23
may‐06
sep‐06
ene‐07
0.38 0.37
may‐07
sep‐07
ene‐08
Moneda
Investment
Funds
22%
Celfin
Investment
Funds
11%
Larrain Vial
Inv. Funds
8%
0.29
may‐08
sep‐08
0.16
ene‐09
0.29
may‐09
sep‐09
4
0.32
ene‐10
CLP/USD = 510

Financial Highlights
Corporate Sales
(dollars in thousands)
$ 103,400
$ 133,100
$ 146,200 $ 162,200 $ 172,900 $ 172,800
2004 2005 2006 2007 2008 2009
EBITDA
(dollars in thousands)
$ 15,000
$ 20,600
$ 21,700
$ 23,400 $ 23,500
$ 31,500
2004 2005 2006 2007 2008 2009
Net Income
(dollars in thousands)
$ 7,900
$ 8,500
$ 11,600
$ 10,900
$ 5,200
$ 16,400
2004 2005 2006 2007 2008 2009
Operating Profit
(dollars in thousands)
$ 11,100
$ 15,400
Non operational
loss mainly due to
exchange rate and
organizational
restructure
$ 18,500 $ 19,700 $ 18,800
$ 25,600
2004 2005 2006 2007 2008 2009
CLP/USD = 510
5

Product Divisions
Rx Marketing Division
� Represents 45% of total sales.
� Subsidiaries (Silesia, MasterCare, ABL Pharma)
are focused primarily in prescription
medications.
� Cardiology, Neuropsychiatry, Genecology,
Dermatology, Pediatrics and Hospital drugs
represent some of our primary strategic
therapeutic areas.
OTC‐UTC Division
� Represents 23% of Chilean national sales and
19% of corporate sales.
� 2nd leading OTC provider in Chile.
� Solid competency in direct‐to‐consumer and
trade marketing.
Generics Division
� 25% of total Chilean national sales.
� More than 180 presentations.
� 2nd leading generics provider in Chile.
Chile Pharma Sales by Product Division
(dollars in millions)
$ 33
$ 37
$ 34
$ 69
$ 68
$ 67
$ 30
$ 34
$ 37
Generic Rx UTC+OTC Clinic
Products
� Strong recognition, satisfaction and
acceptance among doctors and patients.
� Products manufactured through total quality
and GMP industrial methodologies certified by
Chile and Colombia.
� In addition to its own highly regarded
proprietary products, Andrómaco provides a
wide range of recognized and prominent
licensed products.
$ 1
2007
2008
2009
$ 2
6

Licenses and Strategic Alliances
Corporate Pharma Sales 2009
(dollars)
Generic
Prods
20%
OTC+UTC
Prods
22%
Licensed
Prescription
Prods
16%
Propietary
Prescription
Prods
42%
� Empresas Andrómaco’s partners have ready
access to comprehensive and efficient
marketing to medical professionals throughout
the region.
� The Company has received licenses from over
50 leading pharmaceutical companies for the
Central and South American market for more
than 125 products.
� Argentina: Gador, Phoenix, Andromaco Argentina
� Austria: Reisenberger GmbH
� Canada: Pharmascience
� Chile: Biosano
� Costa Rica: Newport
� Denmark: Lundbeck, Novonordisk, Nycomed, Leo, Statem
Serum
� France: Pierre Fabre Dermocosmetic, Pierre Fabre
Medicament, Fournier
� Germany: Sankyo, Schwabbe, Grünenthal, Fujisawa, AMG Int.
� India: Cipla, Claris, Dr. Reddys, Gland Pharma, Ind‐Swit Ltd,
Pure, Ranbaxy
� Italy: Alfawasserwan, Boehringer Ingelheim Italy, Chiesi,
Foltene, Recordati, Rottapharm, SPA
� Japan: Hisamitsu, Taisho, Mitsubishi
� Mexico: Aplicaciones Farmacéuticas
� Neatherlands: Nutricia
� Spain: Bioibérica, Eurogine, Ferrer, Isdin, Lab. Esteve, Lab.
Viñas, Phivor, Robert, Uriach
� Switzerland: Helsinn, Om, TRB Chemedica, Vifor
� United States: Mallinkrodt, Host Pharma,Gen Probe,Three
Rivers Pharmaceuticals
7

Commercial Approach
� Physician
� Provide clinical and therapeutic research information to doctors allowing them access to updated
pharmaceutical knowledge.
� One on one marketing according to their profile and prescription preferences.
� Institutional Clinical MD and personnel
� Patient
� Create exceptional added value with novel healthcare solutions for institutional markets.
� Offer a broad range of high quality products and commit to excellence in service
� Understand our product consumers, go ahead of their needs and provide informative and
educative support through informational web sites, call centers, patient support groups, and
special fidelity programs.
� Pharmacist
� Consider point of sales as an ally, an important part of the commercialization cycle in which they
interact with the patients who buy our products.
8

Clients
� Excellent client relationships guarantee
profitable long term business agreements.
� In Chile, Andromaco is the primary supplier of
medicines to CENABAST, the largest buyer and
distributor of Chile’s public health institutions
(hospitals).
� Sales in the hospital and public health sector
has grown to be 44% of corporate sales in
units. Sales in this area grew 7%.
� Empresas Andrómaco provides fast and
efficient online services for its customers as
well as EDI services (electronic orders).
� The Company’s effective distribution network
provides rapid access to health products in
every major city of each country where we do
business.
Corporate Pharma Sales 2009
(dollars)
Pharmacy
Chains
49%
Hospitals/
Public Inst.
26%
Retail
1%
Wholesaler
17%
Independent
Pharmacies
7%
9

Research, Development & Outlicensing
� The Company actively participates in crucial basic research for therapeutic innovations in a wide variety
of medical specialties.
� Currently, the Company has established important strategic alliances with the following universities and
other prestigious national and international institutions:
� Population Council and The Rockefeller Foundation
� The Conrad Foundation
� University of Sao Paulo, Brazil
� University of La Frontera, Chile
� University of Concepción, Chile
� Chilean Institute of Reproductive Medicine (ICMER)
� Products developed, marketed and outlicensed
� Progering: innovative contraceptive vaginal ring for breastfeeding
� Fertiring: provides timed release hormone supplementation for
women without normal progesterone secretion for in‐vitro
fertilization procedures
� Actiser T: testosterone replacement therapy
10

Facilities
� Manufacturing Facilities. Santiago, Chile.
� Ground : 25.740 m2
� Offices : 3.250 m2
� Quality Control : 120 m2
� Workshop : 250 m2
� Production Plants:
� Hormonal Plant : 610 m2
� Non Hormonal Plant : 1.130 m2
� Liquids Plant : 1.940 m2
� Warehouse : 2.440 m2
� Production Capacity (annual, 3 shifts per day)
� Non Hormonal Tablets/Capsules : 204.400.000 units
� Hormonal Tablets/Capsules : 20.400.000 units
� Liquids : 28.300.000 units
11

Organizational Chart
Perú
Bolivia
Ecuador
Colombia
Panamá
Costa Rica
El Salvador
Guatemala
R. Dominicana
Fernando
Muñoz
12

Market Arena
� Headquartered in Chile, the Company serves
Latin America through commercial
subsidiaries in Peru, Bolivia, Ecuador,
Colombia, Costa Rica, Panama, El Salvador,
Guatemala, Dominican Republic as well as its
network of distributors in Paraguay, Uruguay
and other Central American nations.
� Empresas Andrómaco employs more than
1,200 professionals in manufacturing, sales,
promotion and distribution operations.
� To meet unique regional and customer needs
Andrómaco produces and imports in excess of
500 products, marketed in over 1,300 distinct
formulations in private and public markets.
� Production facilities are located in Santiago,
Chile.
Guatemala
El Salvador
Costa Rica
Ecuador
Medical Sales Reps
Bolivia 30
Chile 250
Colombia 40
Costa Rica 10
Ecuador 80
El Salvador 10
Guatemala 15
Panamá 20
Peru 135
R. Dominicana 25
TOTAL 615
Panamá
Perú
Chile
Haití
República Dominicana
Colombia
Bolivia
Paraguay
Uruguay
13

IMS Private Markets
PAIS (+000) 2008 2009 +/-08/09 2008 2009 +/-08/09 2009
UN-T.UNITS UN-T.UNITS VAR. UN US-T.USD US-T.USD VAR. US PRECIO PROM
TOTAL 945,293 965,407 2.13 5,723,517 5,584,412 -2.43
5.78
COLOMBIA 291,694 298,199 2.23 1,747,959 1,540,127 -11.89
5.16
CHILE 224,637 223,671 -0.43 1,069,543 978,418 -8.52
4.37
ECUADOR 159,286 171,242 7.51 749,390 835,722 11.52
4.88
PERU 98,467 96,385 -2.11 701,461 680,383 -3.00
7.06
DOMINICANA 38,339 38,795 1.19 368,739 395,050 7.14
10.18
GUATEMALA 42,335 41,706 -1.48 347,275 343,342 -1.13
8.23
COSTA RICA 22,751 23,058 1.35 242,208 257,912 6.48
11.19
EL SALVADOR 22,188 21,136 -4.74 194,678 188,889 -2.97
8.94
PANAMA 22,382 23,428 4.67 171,890 186,625 8.57
7.97
BOLIVIA 23,215 27,788 19.70 130,375 177,945 36.49
6.40
* mat ago 2009
7%
5%
6%
12%
3%
3%
3%
15%
28%
18%
COLOMBIA
CHILE
ECUADOR
PERU
DOMINICANA
GUATEMALA
COSTA RICA
EL SALVADOR
PANAMA
14

TOTAL BOLIVIA COLOMBIA COSTA RICA CHILE ECUADOR EL SALVADOR GUATEMALA PANAMÁ PERÚ R. DOMINICANA
Población (est. Jul 2009) 153,887,180 9,775,246 45,664,023 4,253,877 16,601,707 14,573,101 7,185,218 13,276,517 3,360,474 29,546,963 9,650,054
Gasto US$/persona anual 36.3 18.2 33.7 60.6 58.9 57.3 26.3 25.9 55.5 23.0 40.9
USD '000 TOTAL BOLIVIA COLOMBIA COSTA RICA CHILE ECUADOR EL SALVADOR GUATEMALA PANAMÁ PERÚ R. DOMINICANA
TOTAL US$ 5,584,412 177,945 1,540,127 257,912 978,418 835,722 188,889 343,342 186,625 680,383 395,050
Precio Promedio 5.78 6.40 5.16 11.19 4.37 4.88 8.94 8.23 7.97 7.06 10.18
% Crecimiento ‐2.43% 36.49% ‐11.89% 6.48% ‐8.52% 11.52% ‐2.97% ‐1.13% 8.57% ‐3.00% 7.14%
% Peso 100.00% 3.19% 27.58% 4.62% 17.52% 14.97% 3.38% 6.15% 3.34% 12.18% 7.07%
TOTAL UN 965,407 27,788 298,199 23,058 223,671 171,242 21,136 41,706 23,428 96,385 38,795
% Crecimiento 2.13% 19.70% 2.23% 1.35% ‐0.43% 7.51% ‐4.74% ‐1.48% 4.67% ‐2.11% 1.19%
ETICO US$ 5,179,595 165,247 1,375,419 239,896 918,343 784,660 173,039 326,313 175,167 646,116 375,395
% Crecimiento 6.76% 37.40% 8.97% 4.80% ‐8.69% 20.66% ‐2.10% 3.49% 13.31% 8.94% 8.98%
GENERICO US$ 404,817 12,698 164,708 18,016 60,075 51,062 15,850 17,029 11,459 34,267 19,655
% Crecimiento ‐5.18% 37.38% ‐14.11% 3.94% ‐5.73% 10.43% ‐1.60% ‐2.48% 7.97% ‐5.06% 7.09%
EMPRESAS ANDROMACO 90,519 2,687 260 1,532 63,695 4,683 309 1,119 2,571 13,585 78
Precio Promedio 6.67 9.38 15.93 9.33 6.14 5.71 12.98 7.44 12.13 9.02 9.57
% Crec US$ 0.52% 32.77% ‐26.08% 18.16% ‐2.43% 17.15% 72.00% 31.39% 41.95% ‐4.30% 26.94%
I Evol US$ 103 97 84 111 107 105 177 133 131 99 118
% MS US$ 1.62% 1.51% 0.02% 0.59% 6.51% 0.56% 0.16% 0.33% 1.38% 2.00% 0.02%
*MAT Agosto 2009
IMS Private Markets
15

Our Companies
Corporate Sales by Subsidiary 2009
(dollars)
Andrómaco
66%
www.empresasandromaco.cl
Mastercare
1%
Silesia
15%
Diagnotec
1%
ABL
17%
16

LABORATORIOS ANDRÓMACO S.A.
� Andrómaco Laboratories initiated operations in Chile in 1942 and already in the first market evaluations
carried out in 1977, the company began to appear among the ten more important companies of the
sector .
� Since 1980 it has been continuously positioned among the first five laboratories of the Chilean
pharmaceutical market and today is a leading company in the ethical products marketing.
� In addition to the prescription market, it has a supply of high technology and generic products, and
participates strongly in the OTC and institutional markets.
17

ABL Pharma
� It is the trade mark by which the Andrómaco
Companies operate in the foreign market,
bringing, mainly own and licensed ethical
products to the regional markets.
� It is composed by
� ABL Pharma Bolivia, 1993
� ABL Pharma Peru, 1995
� ABL Pharma Ecuador, 2002
� ABL Pharma Costa Rica, 2004
� ABL Pharma Panama, 2004
� ABL Pharma Colombia, 2005
� ABL Pharma El Salvador, 2006
� ABL Pharma R. Dominicana, 2007
� ABL Pharma Guatemala, 2007
ABL Pharma Sales 2009
(dollars in thousands)
Perú
56%
Bolivia
7%
Ecuador
17%
Colombia
2%
Central Am
18%
18

LABORATORIOS SILESIA S.A.
� With more than 50 years in the market, Silesia is a laboratory of specialties with medical prescription
products for women of high quality and recognition in the medical field, within which there is an ample
hormonal products range, specially its contraceptives and hormonal replacement therapy products.
� Incorporated in the year 2005 to the Andrómaco Group of Companies, today is fundamentally oriented
to women's health and quality of life with products highly present in the areas of Gynecology,
Neurospsychiatry and Dermatology, among others.
� Its portfolio includes an important number of licensed products.
19

MASTERCARE
� MasterCare markets and commercializes novel healthcare solutions specially developed to be used in
hospitals and clinics. The products and services address prevention, diagnosis and treatment of
diseases.
� Arranged in three operative divisions, our global mission is to create exceptional added value in
healthcare. These three units are:
� Pharmaceutical
� Specialized Medical Disposable Devices
� Diagnostics
� Team
� Commercial oriented
� Very well trained
� Experienced
� Immediate access to health authorities
� Solid public tender expertise
20

FERRER ANDROMACO
� It is a joint‐venture company with Ferrer Spain created in 2004, that reflects the company decision to
search for different commercial association structures to accede to state‐of‐art products. Ferrer‐
Andrómaco supplies highly sophisticated technological products, to be used for diseases require
therapies of high specificity.
� This association expresses the confidence the Andromaco Companies arises in international companies.
Ferrer is one of the most important Spanish conglomerates with a high participation in the European
Community pharmaceutical market.
DIAGNOTEC
� Diagnotec is leader in the domestic market and a pioneer in the induction of molecular diagnostics
industries in aquaculture, swine and food.
� Diagnotec develops ictiopatologic services, molecular diagnostic, genetic integrated management
programs and biological evaluation
� Diagnotec, developed the first antiviral treatment for control of IPNv, the highest incidence of the virus
in farmed salmon in the world. The company has already conducted trials of these compounds in
antiviral ground for its next launch in the country and is under patent in Europe (including Norway),
U.S., Canada and Chile.
21

Investor Relations
Andrés Rudolphy, CEO
Juan I. Sandoval, CFO
juan.sandoval@andromaco.cl
+56 2 594 84 17
22